1483 studies found for:    "Melanoma"
Show Display Options
Rank Status Study
1 Unknown  Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.
Conditions: Malignant Skin Melanoma T0;   Stage III Melanoma;   Stage IV Melanoma;   Amplification
Intervention: Drug: Nilotinib
2 Completed
Has Results
Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma
Conditions: Melanoma;   Malignant Melanoma;   Melanoma, Experimental;   Experimental Melanomas
Interventions: Biological: aldesleukin;   Biological: therapeutic autologous lymphocytes;   Drug: Cyclophosphamide;   Drug: Fludarabine phosphate;   Radiation: Total body irradiation
3 Completed Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma
Conditions: Stage IV Melanoma;   Stage III Melanoma;   Recurrent Melanoma
Interventions: Drug: dendritic cell-gp100-MART-1 antigen vaccine;   Drug: sargramostim
4 Terminated
Has Results
Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma
Conditions: Melanoma;   Malignant Melanoma;   Melanoma, Experimental
Interventions: Drug: DMF5 Melanoma Reactive TIL;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin
5 Withdrawn Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
Conditions: Melanoma;   Recurrent Melanoma;   Stage III Melanoma;   Stage IV Melanoma
Interventions: Drug: sorafenib tosylate;   Drug: temsirolimus
6 Completed
Has Results
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Intervention: Drug: dasatinib
7 Recruiting Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IIB Melanoma (Locally Advanced);   Stage IIC Melanoma (Locally Advanced);   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma (Limited, Resectable)
Interventions: Drug: dabrafenib;   Drug: trametinib;   Other: laboratory biomarker analysis
8 Completed Phase II Trial of Allovectin-7® for Metastatic Melanoma
Conditions: Melanoma;   Metastatic Melanoma;   Malignant Melanoma;   Skin Cancer
Intervention: Genetic: Allovectin-7®
9 Recruiting INCB024360 and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma
Conditions: Mucosal Melanoma;   Recurrent Intraocular Melanoma;   Recurrent Melanoma;   Stage IIIA Intraocular Melanoma;   Stage IIIA Melanoma;   Stage IIIB Intraocular Melanoma;   Stage IIIB Melanoma;   Stage IIIC Intraocular Melanoma;   Stage IIIC Melanoma;   Stage IV Intraocular Melanoma;   Stage IV Melanoma
Interventions: Drug: IDO1 inhibitor INCB024360;   Biological: MELITAC 12.1 peptide vaccine;   Other: laboratory biomarker analysis
10 Completed Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma
Conditions: Stage IV Melanoma;   Stage III Melanoma;   Recurrent Melanoma
Intervention: Drug: allovectin-7
11 Completed Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma
Conditions: Recurrent Melanoma;   Stage IA Melanoma;   Stage IB Melanoma;   Stage IIA Melanoma;   Stage IIB Melanoma;   Stage IIC Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma
Interventions: Biological: HPV 16 E7:12-20 peptide vaccine;   Biological: gp100:209-217(210M) peptide vaccine;   Other: laboratory biomarker analysis
12 Completed Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma
Conditions: Stage IV Melanoma;   Stage III Melanoma;   Recurrent Melanoma
Interventions: Drug: allovectin-7;   Drug: allovectin-7/dacarbazine;   Drug: dacarbazine
13 Terminated A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma
Conditions: Melanoma;   Malignant Melanoma;   Metastatic Melanoma
Intervention: Drug: 131I-TM601
14 Recruiting Study of IDO Inhibitor in Combination With Ipilimumab for Adult Patients With Metastatic Melanoma
Conditions: Metastatic Melanoma;   Stage III Melanoma;   Stage IV Melanoma
Interventions: Drug: Indoximod;   Drug: Ipilimumab
15 Completed Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IA Melanoma;   Stage IB Melanoma;   Stage IIA Melanoma;   Stage IIB Melanoma;   Stage IIC Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Biological: gp100:209-217(210M) peptide vaccine;   Biological: HPV 16 E7:12-20 peptide vaccine;   Other: laboratory biomarker analysis
16 Recruiting LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations
Conditions: Stage III Melanoma;   Stage IV Melanoma;   Unresectable Melanoma;   BRAF Mutant Melanoma
Intervention: Drug: BRAF inhibitor dabrafenib and MEK inhibitor trametinib
17 Recruiting Molecularly Targeted Therapy in Treating Patients With Melanoma That is Metastatic or Cannot be Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Other: cytology specimen collection procedure;   Drug: molecularly targeted therapy;   Procedure: therapeutic procedure;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
18 Completed Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma
Conditions: Stage IV Melanoma;   Recurrent Melanoma
Intervention: Biological: recombinant interferon beta
19 Recruiting Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma
Conditions: Stage III Melanoma;   Stage IV Melanoma;   Unresectable Melanoma
Intervention: Drug: Pazopanib and Paclitaxel
20 Not yet recruiting Efficacy of Propranolol Treatment to Prevent Melanoma Progression
Conditions: Stages III Skin Melanoma;   Stages II Skin Melanoma;   Stage IB Skin Melanoma
Interventions: Drug: Propranolol hydrochloride;   Drug: Placebo pill

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years